AIM-HIGH trial
AIM-HIGH was a multi-center clinical trial related to the prophylactic treatment of coronary artery disease involving approximately 90 sites in the United States and Canada, which was conducted between 2006 and 2012 and involved 3,414 volunteers.[1]
Results
The trial was stopped early due to a demonstrable lack of efficacy for this intervention. The addition of high-dose, extended-release niacin to a statin did increase HDL cholesterol, as expected, but did not reduce cardiovascular events. The analysis also indicated little to no probability that adding high-dose, extended-release niacin to statin treatment would show a benefit even if the study continued to its originally planned completion.
References
- ↑ https://www.nhlbi.nih.gov/node-general/questions-and-answers-aim-high-study National Heart Lung & Blood Institute (USA) Questions and Answers: AIM-HIGH Study, May 26, 2011
 | This medical article is a stub. You can help EverybodyWiki by expanding it. |
This article "AIM-HIGH trial" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:AIM-HIGH trial. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
